What is CYCN stock price today?

CYCN (Cyclerion Therapeutics Inc) stock is trading at $1.34 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is CYCN stock going up or down today?

CYCN stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy CYCN stock now?

The decision to buy CYCN depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is CYCN a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for CYCN based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is CYCN stock overvalued or undervalued?

Use our DCF valuation calculator to determine if CYCN is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is CYCN's P/E ratio?

P/E ratio data for CYCN will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is CYCN's market cap?

CYCN (Cyclerion Therapeutics Inc) has a market capitalization of $0.01 billion, making it a small-cap stock.

What is CYCN's price to book ratio?

CYCN trades at a price-to-book (P/B) ratio of 0.54, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does CYCN pay dividends?

CYCN does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is CYCN's dividend yield?

CYCN does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is CYCN stock a good long-term investment?

CYCN's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is CYCN's revenue growth rate?

CYCN has shown revenue growth of 3.5% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

CYCN is currently operating at a loss. Some companies prioritize growth over profitability in early stages. Review our financial analysis for detailed insights.

What are the risks of investing in CYCN?

Key risks for CYCN include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does CYCN compare to its competitors?

Compare CYCN to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize CYCN's performance and positioning.

What is CYCN's stock price target for 2026?

Our AI model provides price targets for CYCN based on fundamental analysis: Bull case $1.74 (+30%), Base case $1.54 (+15%), Bear case $1.21 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about CYCN?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for CYCN. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is CYCN's next earnings report?

CYCN reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

CYCN - Cyclerion Therapeutics Inc

NYSE * Health Care * Biotechnology

$1.34

$-0.02 (-1.53%)

About Cyclerion Therapeutics Inc

Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

CYCN Key Statistics

Market Cap

$5.18M

P/B Ratio

0.54

EPS

$-0.70

Revenue Growth

+3.5%

Profit Margin

-0.8%

Employees

How CYCN Compares to Peers

CYCN has the fastest revenue growth among competitors

CYCN is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

of 6

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
CYCN(This stock)	$5.18M	N/A	4%	-0.8%	-
AMGNAmgen Inc	$178.24B	25.6	0%	0.2%	vs AMGN
GILDGilead Sciences	$154.03B	19.2	0%	0.3%	vs GILD
VRTXVertex Pharmaceuticals	$113.35B	31.2	0%	0.3%	vs VRTX
REGNRegeneron Pharmaceuticals	$77.77B	17.6	0%	0.3%	vs REGN
BIIBBiogen Inc	$24.26B	15.1	0%	0.2%	vs BIIB

Cyclerion Therapeutics Inc Company Information

Headquarters: Massachusetts; U.S.A
Website: www.cyclerion.com
Sector: Health Care
Industry: Biotechnology

CYCN - Cyclerion Therapeutics Inc

About Cyclerion Therapeutics Inc

CYCN Key Statistics

How CYCN Compares to Peers

Cyclerion Therapeutics Inc Company Information

CYCN Lician Score

CYCN Financial Snowflake

Upcoming Events for CYCN